Login / Signup

Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial.

Rachel A WarrenAllie S CarewPantelis AndreouChristine HermanAndrew P LevyHenry N GinsbergJohn SappEric B RimmSusan KirklandLeah E Cahill
Published in: Diabetes care (2021)
The effect of fenofibrate added to simvastatin on risk of CAD events depends on Hp phenotype in the ACCORD lipid trial.
Keyphrases
  • coronary artery disease
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • fatty acid
  • coronary artery
  • randomized controlled trial
  • open label
  • heart failure
  • left ventricular
  • transcatheter aortic valve replacement